



CrossMark

“Metabolic dysfunction in pulmonary hypertension: from basic science to clinical practice.” Stephen Y. Chan and Lewis J. Rubin. *Eur Respir Rev* 2017; 26: 170094.

Unfortunately, in this article in the December 2017 issue of the *European Respiratory Review*, the details about modulation of peroxisome proliferator-activated receptor (PPAR) γ at the end of the section “Hypoxia-inducible factor and downstream metabolic effectors relevant to the Warburg effect” were not entirely accurate. The final two sentences of this section have been rephrased as follows: “Despite these encouraging findings, the clinical use of older PPAR γ agonists has been tempered by indications of adverse myocardial events [49] and has stymied advances in PH. Nonetheless, the weight of evidence regarding the activity of PPAR γ in PH indicates its potential as a future drug target, particularly for newer PPAR γ agonists [50].” The reference by KERNAN *et al.* [50] has been added, and subsequent references have been renumbered. The article was corrected before printing the December 2017 issue, and has been corrected and republished online.

Copyright ©ERS 2018

ERR articles are open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0